Lorena Tonarelli M.Sc.

Medical Writer, Copywriter, and Journalist

Medical Writing




A senior consultant in market access/HEOR and medical communications, Lorena is a specialist in value strategy and communication. She has over 15 years of professional experience in medical writing and editing, working with market access/HEOR consultancies, med comms agencies, clinical research organisations and pharma companies on a wide range of products, therapy areas and drug classes. Lorena is a member of the European Medical Writers Association (EMWA).  She has a degree of Master of Science in Science and a bachelor's degree (Hons) in Natural Sciences, as well as research laboratory experience.


Global value/reimbursement dossiers • Key value message development and testing • Value stories and propositions • Core value slide decks • Payer/KOL discussion guides and interviewing • Critical assessments of treatment/regulatory/payer/competitor landscapes and addressable patient populations  • Advisory board/KOL meeting reports • Abstracts, posters and slide decks for presentation at conferences • Manuscripts for publication in medical journals • Symposium reviews • Clinical summaries • Publication summaries • Reference packs • Objection handlers • Project proposals • Quality control (QC) • Educational content •

Therapy areas

Oncology (haematologic and solid tumours) • Psoriasis • Atopic dermatitis • Rare diseases (cystic fibrosis) • Primary and secondary immunodeficiency disorders • Asthma • COPD • Chronic rhinosinusitis with nasal polyps • Haematology (anaemia, haemophilia) • Ophthalmology (AMD, glaucoma, diabetic retinopathy, retinoblastoma) • Cardiovascular (stroke, myocardial infarction, cardiac arrest, heart failure, arrhythmias) • Diabetes and related complications (nephropathy, retinopathy) • Neurology (Alzheimer’s disease and other dementias, Parkinson’s disease, multiple sclerosis, epilepsy, ADHD • Rheumatology •

Drug classes

Anti PD-1/PD-L1 and CTLA-4 mAbs • LADD-based immunotherapies • PARP inhibitors • Tyrosine kinase inhibitors (e.g., VEGFR TKIs, HER2 TKIs) • CDK4/6 inhibitors • EGFR/cMet bispecific antibodies • Anti-CD30 antibody-drug conjugates • PCSK9 inhibitors • SGLT2 inhibitors • Anti-TNF monoclonal antibodies • Anti IL-4/IL-13 monoclonal antibodies • IL-23 inhibitors • LAMAs, LABAs • Nonstimulant selective alpha2A-adrenergic receptor agonists • Immunoglobulins • CFTR potentiators • (List is not exhaustive)


In-depth understanding of clinical trials and the pharmaceutical product’s life cycle • Interprets and presents, as text and graphically, clinical as well as budget impact (BI) and cost-effectiveness (CE) data • Familiar with PubMed searches,  reference mark-up, and EndNote use • Supports clients throughout projects, by applying expert therapy area and product knowledge, attending meetings, and addressing amendment requests • Reviews the work of others, including medical writers, KOLs and researchers •


Prime Global • Envision Pharma Group • PAREXEL International Corporation • Bedrock Healthcare Communications • RJW & Partners • E-vate • Porterhouse Medical Group • The European Medical Journal (EMJ) • Celgene Corporation • Novartis Oncology • Medtronic • DDB Remedy • Hayward Medical Comms • Johnson & Johnson • Merck Serono • Pfizer UK • Chandler Chicco Agency • Freiberg Press Inc. • Bupa UK • Curated Digital • Insight-2-Implement • General Electric (GE) Healthcare •

Print Print | Sitemap
© 2019 Lorena Tonarelli, M.Sc. B.Sc. (Hons)